Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity

The new oral anticoagulants have many advantages over warfarin, but one disadvantage is the inability to rapidly reverse their anticoagulant effects. Andexanet, a small-molecule factor Xa fragment, rapidly lowered levels of rivaroxaban and apixaban in older healthy volunteers. The direct factor Xa i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2015-12, Vol.373 (25), p.2413-2424
Hauptverfasser:	Siegal, Deborah M, Curnutte, John T, Connolly, Stuart J, Lu, Genmin, Conley, Pamela B, Wiens, Brian L, Mathur, Vandana S, Castillo, Janice, Bronson, Michele D, Leeds, Janet M, Mar, Florie A, Gold, Alex, Crowther, Mark A
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Aged Anticoagulants Antidotes - pharmacology Antidotes - therapeutic use Blood Coagulation - drug effects Clinical trials Double-Blind Method Factor Xa - metabolism Factor Xa - pharmacology Factor Xa - therapeutic use Factor Xa Inhibitors - adverse effects Factor Xa Inhibitors - therapeutic use Female Hemorrhage Hemorrhage - chemically induced Hemorrhage - drug therapy Humans Inhibitor drugs Male Middle Aged Peptide Fragments - metabolism Prevention Protein Precursors - metabolism Prothrombin Prothrombin - metabolism Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyridones - adverse effects Pyridones - therapeutic use Recombinant Proteins - pharmacology Recombinant Proteins - therapeutic use Rivaroxaban - adverse effects Rivaroxaban - therapeutic use Side effects Thrombin Thrombosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!